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Abstract
Background: Pannexin 1 forms ion and metabolite permeable hexameric channels and is abundantly expressed in
the brain. After discovering pannexin 1 expression in postnatal neural stem and progenitor cells we sought to
elucidate its functional role in neuronal development.
Results: We detected pannexin 1 in neural stem and progenitor cells in vitro and in vivo. We manipulated pannexin
1 expression and activity in Neuro2a neuroblastoma cells and primary postnatal neurosphere cultures to
demonstrate that pannexin 1 regulates neural stem and progenitor cell proliferation likely through the release of
adenosine triphosphate (ATP).
Conclusions: Permeable to ATP, a potent autocrine/paracine signaling metabolite, pannexin 1 channels are ideally
suited to influence the behavior of neural stem and progenitor cells. Here we demonstrate they play a robust role
in the regulation of neural stem and progenitor cell proliferation. Endogenous postnatal neural stem and progenitor
cells are crucial for normal brain health, and their numbers decline with age. Furthermore, these special cells are
highly responsive to neurological injury and disease, and are gaining attention as putative targets for brain repair.
Therefore, understanding the fundamental role of pannexin 1 channels in neural stem and progenitor cells is of
critical importance for brain health and disease.
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Background
The majority of neurons are born embryonically, however
neurogenesis continues in the postnatal brain throughout
life (reviewed in [1]). Postnatal neurogenesis is a complex,
multi-step developmental process that includes cell beha-
viors such as proliferation, differentiation and migration,
and involves several distinct cell types. These stem cell
behaviors are guided, in part, by extracellular stimuli
unique to their specialized microenvironments or ‘niches’:
the subgranular zone (SGZ) of the dentate gyrus and the
ventricular zone (VZ) of the lateral ventricles (Figure 1A).
Postnatal NSCs in the VZ generate large numbers of ol-
factory bulb interneurons. The distinct neural stem and
progenitor cell (NSC/NPC) types implicated in this neuro-
genic process are characterized by their morphology and
differential expression of lineage markers (Figure 1A).
Radial glia-like cells (known as type B cells in VZ) express
the filament markers nestin and glial fibrillary acidic pro-
tein (GFAP) (as well as several other lineage markers).
Electron microscopy has shown that the ependymal layer
lining the ventricles is not entirely contiguous and that
type B cells make direct contact with the ventricle either
via a large luminal surface or a thin cellular process
(Figure 1A) [3-8]. These cells subsequently generate highly
proliferative intermediate, transit-amplifying NPCs (C cells)
that lose GFAP expression. Finally, further differentiation
gives rise to migratory neuroblasts (A cells), which are
committed to a neuronal lineage and express doublecor-
tin (DCX). Following exit of the cell cycle, the immature
neurons express class III beta tubulin, also known as
Tuj-1.
Pannexins (Panx) are four-pass transmembrane proteins
that oligomerize to form large pore ion and metabolite-
permeable channels. Building on accumulating evidence
that the coordinated activity of ion channels plays a major
role in all aspects of NSC/NPC biology [9], we recently
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entiation by impacting on neurite outgrowth and the tim-
ing of NSC/NPC commitment to a neuronal lineage [10].
Another Panx family member, Panx1, is also widely
expressed in the brain as well as being found in the per-
iphery [11-15]. Panx1 forms large hexameric pores at the
Figure 1 Panx1 is expressed in nestin-positive periventricular NSC/NPCs throughout postnatal development in vivo. (A) Mouse brain
schematic with the neurogenic ventricular zone (VZ) and subgranular zone (SGZ) regions highlighted (i). Cell types throughout neurogenesis and
the lineage markers expressed at each stage. Relatively quiescent NSCs become highly proliferative NPCs, and neuronally committed migratory
neuroblasts before exiting the cell cycle as immature neurons (ii). Schematic of cell types in the periventricular region. The ependymal cell layer is
interdigitated by thin processes or whole luminal surfaces of the radial glia-like NSCs (iii). This figure is a partial reproduction of another figure
created by the same authors that appears in [2] and is reproduced with permission. (B) Western blot of lysates from HEK293T cells overexpressing
EGFP, Panx1EGFP, or Panx1, showing specificity of the Panx1 Cterm antibody. (C) Confocal images of murine brain slices at the periventricular
region. Nestin-positive NSCs exhibit high levels of Panx1 co-expression in postnatal day 15 (P15) (i), P30 (ii) and P60 (iii) brains. Arrows indicate
areas of co-expression. (D) Image from a confocal z-stack with orthogonal side-views of a P30 periventricular region. Panx1 expression is noted in
ependymal/sub-ependymal layers. (E) Confocal image from a P15 periventricular region. Panx1 is absent from DCX-positive neuroblasts.
Hoechst 33342 was used as a nuclear counterstain in C-E. All scalebars 10 μm. DCX, doublecortin; NPC, neural progenitor cells; NSC, neural
s t e mc e l l s ;P a n x 1 ,p a n n e x i n1 ;V ,v e n t r i c l e .
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membrane, depending on the cell type, and is permeable
to ions and ATP in neurons, astrocytes and microglia
[16-21]. Purinergic nucleotides act as proliferation sig-
nals for NSC/NPCs, serving as negative regulators of ter-
minal neuronal differentiation [22-25]. NSC/NPCs express
P2Yand P2X7 receptors and release ATP in episodic burst
events, which act in an autocrine and paracrine manner to
induce proliferation and negatively regulate differentiation.
We have discovered Panx1 expression in postnatal NSC/
NPCs. As large pore channels that mediate ATP release,
we hypothesized that Panx1 channels might be positively
associated with NSC/NPC proliferation.
Here we combine studies in the Neuro-2a (N2a) murine
neuroblastoma-derived cell line as model NSC/NPCs, and
VZ NSC/NPCs in vitro and in vivo, to elucidate the role
of Panx1 in postnatal neuronal development. We detected
Panx1 in nestin-positive and GFAP-positive NSC/NPCs
and Tuj1-positive immature neurons, but not in inter-
mediate DCX-positive neuronally committed neuroblasts
in vitro and in vivo. Panx1 mediated ATP release, and
blocking P2 purinergic receptors reduced cell prolifera-
tion, suggesting a possible role for Panx1 in regulating
cell proliferation. Finally, by modulating Panx1 expres-
sion and activity in N2a cells and VZ neurosphere cul-
tures, we demonstrated that Panx1 regulates NSC/NPC
proliferation.
Results
Panx1 is expressed in periventricular NSC/NPCs
Using confocal immunofluorescence microscopy, we exam-
ined coronal cryosections of the postnatal periventricular
area ranging from postnatal day 15 (P15) to P60 with
lineage-marker antibodies (Figure 1C) and for Panx1 ex-
pression with an antibody (anti-Panx1 Cterm rabbit poly-
clonal, Invitrogen/Life Technologies, Burlington, Ontario,
Canada) that we had previously characterized by immuno-
blotting of lysates from human-embyonic kidney (HEK)
293T cells transfected with Panx1, Panx1EGFP and EGFP
(Figure 1B). Panx1 was detected in a sub-population of
nestin-positive/GFAP-positive type B cells and nestin-
positive type C cells in the ependymal/sub-ependymal
layer of both the dorsal (Figure 1C, D) and ventral (not
shown) aspects of the lateral ventricles. Panx1 was absent
from DCX-positive committed neuroblasts (Figure 1E).
These results suggest that Panx1 is expressed in periven-
tricular NSC/NPCs and is lost upon neuronal commitment.
Panx1 mediates ATP release from NSC/NPCs
To further study the properties and cell biology of Panx1
in neuronal development we moved to in vitro culture
models. We first employed the N2a cell line to examine
the ability of Panx1 expression to influence ATP release
from NPCs and to confirm the effects of blocking P2
receptors on NPC proliferation. The N2a cell line, derived
from a murine neuroblastoma, is a widely used NPC
model as these cells can be differentiated in the presence
of retinoic acid and low serum [10,26,27]. N2a cells ex-
press endogenous Panx1 (Figure 2A). Panx1 is known to
be activated by elevated K+[28,29], which can rise above
resting levels as much as 5 mM during periods of intense
neuronal activity, up to more than 20 mM during injury
and even higher during waves of spreading depression
(reviewed in [30]). We treated N2a cells with varying
concentrations of extracellular KCl, and found that ATP
release was stimulated by elevating KCl concentrations
(20 mM) compared to control (5.33 mM) and 0 mM KCl
(P<0.01 for one-way analysis of variance (ANOVA)
with Tukey post-hoc, N=3) (Figure 2B). Furthermore,
Figure 2 Panx1 blockage decreases ATP release from N2a cells
and blocking P2 receptors reduces cell proliferation. (A) Panx1 is
endogenously expressed in N2a cells, as demonstrated by RT-PCR (i)
and western blot analysis (ii). To the left of the western blot, the
asterisk (*) above the arrow denotes high-molecular weight species
likely representing various Panx1 oligomeric forms, while the asterisk
below the arrow denotes low molecular weight Panx1 cleavage
products consistent in size with those reported in the literature [16].
(B) ATP release from N2a cells was stimulated upon treatment with
20 mM KCl buffer compared to control (5.33 mM) and 0 mM KCl
conditions ((**) P<0.01 for one-way ANOVA with post-hoc Tukey’s
multiple comparison test, N=3). (C) Blockage of Panx1 channels with
0.5 mM probenecid significantly decreases stimulated ATP release
from N2a cells compared to controls (60.50±7.913% and
99.17±6.831%, respectively, N=5, P=0.0159 for non-parametric t
test). (D) N2a cell numbers were quantified at 0, 24 and 48 hours for
cells treated with 30 μM PPADS, 1 mM probenecid, or vehicle
control. PPADS and probenecid treatments significantly reduced N2a
numbers at 24 and 48 hours ((*) P<0.05 and (***) P <0.001 for
one-way ANOVA with post-hoc Tukey’s multiple comparison test,
N=3). ANOVA, analysis of variance; Panx, pannexin1, PPADS,
pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid.
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which selectively blocks Panx1 hemichannels, and not
connexin hemichannels [31], significantly decreased ATP
release (60.50±7.913% of control, P=0.0159 for non-
parametric t test) from proliferating N2a cells when com-
pared to controls (Figure 2C). This is in accordance with
the reported role of Panx1 in mediating ATP release in nu-
merous other cell types (reviewed in [17]). The remaining
ATP release could possibly be mediated by a vesicular re-
lease mechanism [32] or by connexin hemichannels ([33],
but see also [34]). Finally, blocking Panx1 with probenecid
(24 hours: control=6.9×10
4±6.4×10
3 cells, probenecid=
4.1×10
4±1.8×10
3 cells, P<0.001; 48 hours; control=1.1×
10
5±4.8×10
3 cells, probenecid=5.6×10
4±4.7×10
3 cells,
P<0.001 for one-way ANOVA with Tukey post-hoc), or
P2 receptors with pyridoxalphosphate-6-azophenyl-2′,4′-
disulfonic acid (PPADS) [34], which blocks several P2X
and P2Y isoforms [35-42], significantly reduced N2a cell
proliferation (24 hours: control=6.9×10
4±6.4×10
3 cells,
PPADS=4.6×10
4±5.3×10
3 cells, P<0.05; 48 hours:
control=1.1×10
5±4.8×10
3 cells, PPADS=8.1×10
4±
4.4×10
3 cells, P<0.001 for one-way ANOVA withTukey
post-hoc) in accordance with the previously described role
of P2 receptors in regulating NPC proliferation (Figure 2D)
[22-25].
Panx1 plays a major role in regulating VZ NSC/NPC
proliferation
Given that Panx1 mediates ATP release in N2a model
NPCs and that blocking P2 purinergic receptors inhibits
proliferation, as shown in Figure 2, we hypothesized that
Panx1 regulates NSC/NPC proliferation. To investigate the
effect of Panx1 on N2a cell proliferation we overexpressed
Panx1, and conversely, blocked Panx1 channels with pro-
benecid [31]. Expression of Panx1EGFP, which localizes
mainly at the plasma membrane in N2a cells (Figure 3A),
as was previously reported in HEK293T cells [43],
reduced the doubling time of N2a cells from 26.2 hours
to 14.7 hours (cell counts increased by approximately
50%, P<0.01 for one-way ANOVA with Tukey post-hoc,
at 72 hours P<0.001 for one-way ANOVA with Tukey
post-hoc, N=3) (Figure 3B) suggesting a positive effect
of Panx1 on proliferation. Similarly, probenecid sig-
nificantly reduced the proliferation of control EGFP
expressing N2a cells, which endogenously express Panx1
(from 1.2×10
5±1.1×10
4 cells to 4.0×10
4±4.9×10
3
cells, P<0.01 for one-way ANOVA with Tukey post-
hoc, N=3), as well as Panx1EGFP overexpressing cells
(from 1.8×10
5±2.4×10
4 cells to 6.0×10
4±8.0×10
3 cells,
P<0.001 for one-way ANOVA with Tukey post-hoc,
N=3) (Figure 3C).
Figure 3 Panx1 regulates N2a cell proliferation. (A) Image from a confocal z-stack with orthogonal side-views of N2a cells overexpressing
Panx1EGFP. Panx1 is highly localized to the plasma membrane, stained with wheat germ agglutinin (WGA), as well as to intracellular membranes.
(B) N2a cells overexpressing Panx1 exhibited a reduced doubling time (14.7 hours) compared to control cells overexpressing EGFP (26.2 hours) ((*)
P<0.05 and (**) P<0.01 for one-way ANOVA with post-hoc Tukey’s multiple comparison test, N=3). (C) Treatment of transfected N2a cells with
the Panx1 channel blocker, probenecid (1 mM), significantly reduced cell proliferation at 48 hours in both Panx1 and EGFP overexpressing cells
((**) P<0.01 and (***) P<0.001 for one-way ANOVA with post-hoc Tukey’s multiple comparison test). ANOVA, analysis of variance; Panx1,
pannexin1.
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eration of primary NSC/NPCs, we created neurosphere
cultures from neonatal mice (P0 to P3), as previously
described [10,44] (Figure 4A). Panx1 mRNA and protein
were expressed in VZ (and SGZ) derived neurosphere
cultures, maintained for seven days in vitro (DIV), as
assessed by RT-PCR and western blotting (Figure 4B).
Confocal immunofluorescence microscopy of VZ neuro-
sphere cultures with lineage markers confirmed Panx1
expression in nestin-positive/GFAP-positive NSCs and
nestin-positive/GFAP-negative NPCs (Figure 4C). Fur-
thermore, we plated VZ neurospheres on poly-D-lysine
in the absence of mitogenic growth factors to induce
differentiation, in order to investigate whether Panx1 is
expressed in neuronally committed DCX-positive neuro-
blasts or Tuj-1-positive immature neurons by confocal
immunofluorescence microscopy. As we observed in vivo,
Panx1 immunoreactivity was absent in DCX-positive
Figure 4 Panx1 expression in NSC/NPCs is re-capitulated in vitro in neurosphere cultures. (A) Outline of neurosphere culture generation
from P0 to P3 hippocampus or microdissected VZ. Spheres are cultured for seven days in vitro (DIV) with addition of growth factors (hEGF and
bFGF) every two DIV, before harvesting for subsequent analyses, or differentiation by removal of growth factors and plating on a poly-D-lysine
coated surface. (B) Panx1 mRNA (i) and protein (ii) are expressed in VZ and SGZ neurospheres. To the left of the western blot, the asterisk (*)
above the arrow denotes high-molecular weight species likely representing various Panx1 oligomeric forms, while the asterisk below the arrow
denotes low molecular weight Panx1 cleavage products consistent in size with those reported in the literature [16]. (C) Confocal images showing
Panx1 expression in a cryosectioned undifferentiated VZ neurosphere (i) and a digitally zoomed z-stack with orthogonal side-views (ii) in nestin-
positive/GFAP-positive and nestin-positive/GFAP-negative cells. (D) Image from a confocal z-stack with orthogonal side-views of Panx1 expression
in DCX-negative cells in a differentiated VZ neurosphere. (E) Image from a confocal z-stack with orthogonal side-views showing high levels of
Panx1 co-expression with Tuj-1 in immature neurons from a differentiated VZ neurosphere. Hoechst 33342 was used as a nuclear counterstain in
C-E. Scalebars 10 μm. DCX, doublecortin; GFAP, glial fibrillary acidic protein; NPC, neural progenitor cells; NSC, neural stem cells; Panx1, pannexin1;
SGZ, subgranular zone; VZ, ventricular zone.
Wicki-Stordeur et al. Neural Development 2012, 7:11 Page 5 of 10
http://www.neuraldevelopment.com/content/7/1/11neuroblasts cultured under these neuronal driving con-
ditions (Figure 4D). Finally, Panx1 was detected in Tuj-1
positive immature neurons (Figure 4E), consistent with
previously reported neuronal Panx1 expression [10,45].
We then examined the impact of the Panx1-blocker,
probenecid, on the proliferative capacity of VZ neuro-
sphere cultures. Neurospheres were cultured in the
absence or presence of 1 mM probenecid from DIV1
onwards. Neurospheres were observed each day by light mi-
croscopy and diameter was measured on DIV7 (Figure 5A).
Probenecid-treated neurospheres were significantly smal-
ler than controls (41.85±1.649 μm and 93.97±5.089 μm,
respective1y, P<0.0001 for non-parametric t test, N=12)
(Figure 5B).
Discussion
Here we report the discovery of Panx1 expression in
NSC/NPCs both in vivo and in vitro. In vivo, Panx1 ex-
pression was primarily found in luminal type B NSCs
and in some sub-ependymal NSCs. As described above,
electron microscopy has shown that the ependymal layer
lining the ventricles is not entirely contiguous and that a
large proportion of type B cells make direct contact with
the ventricle either via a large luminal surface or a thin
cellular process [3-8]. Panx1 block by probenecid reduced
NSC/NPC proliferation, while overexpression of Panx1
increased proliferation. Although the Panx1 blocker pro-
benecid is also known to target organic anion transporters
[46,47], the increase in cell proliferation caused by Panx1
overexpression was almost completely blocked by pro-
benecid suggesting that this is a Panx1-specific effect.
As large pore ion and metabolite-permeable channels,
Panx1 make ideal integrators of neurogenic microenviron-
ment signaling in the periventricular region. Accordingly,
our results demonstrate a role for Panx1 in the regulation
of NSC/NPC proliferation, in part, through mediating the
release of ATP (or similar nucleotides like ADP and UTP)
that subsequently acts on P2 purinergic receptors [22-25].
Here we induced ATP release by stimulating the cells with
elevated extracellular potassium (20 mM), and found a
significant reduction in this stimulated release upon
probenecid treatment. ATP is also basally secreted in
bursts from NSC/NPCs. In other cell types, ATP acti-
vates Panx1 channels in a P2-receptor-dependent man-
ner [48]. A similar nucleotide (ATP, ADP or UTP)-
dependent positive feedback mechanism could account
for the increased proliferation observed under Panx1
overexpression, as proliferation is blocked by the P2
Figure 5 Panx1 regulates primary NSC/NPC proliferation. (A) Outline of neurosphere treatments in vitro. Growth factors (hEGF and bFGF)
were added every two DIV beginning at DIV0, while the Panx1 blocker probenecid was added at DIV1 to a concentration of 1 mM. Sphere
diameter was measured at DIV7. (B) Brightfield images of vehicle and probenecid treated spheres (i). A significant reduction in neurosphere
diameter was observed following probenecid treatment compared to vehicle treatment (41.85±1.649 μm and 93.97±5.089 μm respectively,
P<0.0001 for non-parametric t test, N=12) (ii). DIV, days in vitro; NPC, neural progenitor cells; NSC, neural stem cells; Panx1, pannexin 1.
Wicki-Stordeur et al. Neural Development 2012, 7:11 Page 6 of 10
http://www.neuraldevelopment.com/content/7/1/11receptor blocker PPADS. We did not detect a large in-
crease in basal ATP levels with Panx1 overexpression, but
this is not surprising given the high expression of 5′-
nucleotidase on the surface of NSC/NPCs [22].
What additional signals might be involved in triggering
ATP release from Panx1 in NSC/NPCs? Recently an inter-
action between Panx1 and the actin cytoskeleton was
described [43] in BICR-M1R(k) cells, and Panx1 has previ-
ously been shown to be activated by cell membrane stretch
[18,20]. Multiple cytoskeletal rearrangements occur in
cell division and might perpetuate Panx1 mediated ATP
release and downstream purinergic receptor signaling,
resulting in continued proliferation. Interestingly, we
detected cleavage fragments of Panx1 consistent with
recently reported Panx1 caspase 3 cleavage that results
in constitutive channel opening during apoptosis, and
release of ‘find me’ nucleotide signals necessary for the
recruitment of phagocytic cells [16]. Our knowledge of
the role of caspases has recently expanded from apop-
tosis to include many other non-apoptotic cellular roles,
including cell proliferation and differentiation (reviewed
in [49]). It is tempting to speculate that constitutive Panx1
activity generated by caspase proteolytic cleavage might
also be relevant to, or necessary for, its role in NSC/NPC
proliferation. As PPADS did not reduce proliferation to
the same extent as probenecid (Figure 2), the possibility
exists that other Panx1 mechanisms may be involved in
addition to an ATP/nucleotide release. Using unbiased
proteomic methods, we are actively pursuing the identifi-
cation of Panx1 protein interaction partners specific to
NSC/NPC to elucidate further the signaling pathway(s)
that regulate Panx1 function in NSC/NPCs.
The expression and functional role of Panx2 in NSC/
NPCs was recently described [10]. In accordance with
previous studies in heterologous expression systems [50],
the current study demonstrates Panx1 has a very differ-
ent subcellular distribution profile than Panx2 in NSC/
NPCs. While Panx2 was mainly found in discrete intra-
cellular structures, Panx1 is more widely distributed and
also found at the plasma membrane (Figures 1, 3, 4).
Also, while Panx2 expression was limited to a small sub-
set of cells, Panx1 appears to be abundantly expressed.
Furthermore, recent work suggests that the oligomeric
structures and pharmacological sensitivities of Panx1 and
Panx2 are fundamentally different [51], suggesting that a
physical or functional interaction in NSC/NPCs is unlikely.
During embryonic development, the source of ATP re-
lease from VZ radial glia has been reported to be connexin
43 hemichannels [52]. Panx1 channels have only recently
come into the picture, having been discovered long after
the connexins by homology to the invertebrate innexins
[12]. Given the relatively high embryonic expression of
Panx1 [15] and the data we present here on postnatal
Panx1 expression in postnatal periventricular NSC/NPCs,
it would be interesting, in future studies, to examine
potential crosstalk or overlap between connexin 43 and
Panx1 signaling in NSC/NPCs during embryonic devel-
opment. For example, perhaps there are subpopulations
of NSC/NPCs that express either connexin 43 or Panx1,
or if co-expressed, are coupled to or regulated by differ-
ent signaling paradigms. We do not detect Panx1 in
postnatal migrating neuroblasts whereas connexin 43
appears to be expressed in these cells [53], and has been
shown to play a major role in newborn cell migration
from the periventricular region in the embryonic brain
[54-56]; this suggests that the roles of Panx1 and connexin
43 are functionally and somewhat physically distinct.
Recent studies highlight the reparative potential of
enhancing the proliferation, recruitment and survival of
periventricular neuroblasts (reviewed in [57-59]). To even-
tually harness this potential it is important to understand
the factors regulating the behavior of these cells, including
the role of Panx1. Panx1 ion and metabolite-permeable
channels are known to open in several pathological cir-
cumstances, including elevated extracellular potassium
[28], ischemia [60] and elevated amyloid beta peptide
exposure [21], a pathogenic feature of Alzheimer’sd i s -
ease (AD). NSCs are highly sensitive to changes in their
environment, especially injury and neurological diseases
(reviewed in [61,62]). Some of the changes in neurogenesis
seen with brain injury, stroke and AD could conceivably
involve pathological activation of Panx1 channels in NSC/
NPCs. Therefore, understanding the fundamental role of
Panx1 channels in NSC/NPCs is of high importance for
brain health and disease.
Conclusions
In this study we have established that Panx1 is expressed
in NSC/NPCs where it plays an important role in the posi-
tive regulation of cell proliferation. As previous work has
focused mainly on the role of Panx1 in neuropathology,
this is, to our knowledge, the first demonstration of a
normal physiological role of Panx1 channels in the cen-
tral nervous system. After discovering Panx1 expression
in postnatal VZ NSC/NPCs, in vivo,w et h e ns o u g h tt o
elucidate its functional role in neuronal development by
manipulating Panx1 expression and activity in N2a cells
and primary postnatal neurosphere cultures. We demon-
strated that Panx1 channels mediated ATP release, which
contributes to positive regulation of proliferation through
activation of P2 receptors. Moreover, we found that over-
expression of Panx1 robustly and significantly increased
N2a cell proliferation and that these effects were abro-
gated by the Panx1 blocker, probenecid. Furthermore,
we detected robust Panx1 expression in postnatal VZ
neurosphere cultures. As anticipated, blocking Panx1
activity in these primary NSC/NPC cultures significantly
reduced cell proliferation. Future studies are now needed
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nels in NSC/NPCs, including additional possible mechan-
isms underlying their role in the regulation of proliferation.
Understanding the fundamental roles of Panx1 channels in
NSC/NPCs is of critical importance given the vital roles
that postnatal neurogenesis plays in normal brain health,
as well in the progression of neurological diseases and the
response to brain injury.
Methods
Animals
C57BL/6 mice were used and all procedures were carried
out in agreement with the guidelines of the Canadian
Council for Animal Care and the University of Victoria
Animal Care Committee.
Cell culture
Primary NSC/NPC cultures were isolated from postnatal
day 0 to3 (P0 to P3) C57BL/6 mouse hippocampus and
periventricular zone and expanded as neurospheres for
seven days in vitro (DIV) as described [9,43]. For prolifera-
tion assays, neurospheres were treated at DIV1 with 1 mM
probenecid (Invitrogen), 30 μM pyridoxal phosphate-6-
azophenyl-2′,4′-disulfonic acid (PPADS; Sigma, Oakville,
Ontario Canada) or equivalent volumes of sterile water. At
DIV7, neurospheres were visualized/photographed using
brightfield illumination, and sphere diameters were mea-
sured in Photoshop CS5 (Adobe). N2a cells were cultured
in DMEM/F12 supplemented with 10% fetal bovine serum
(FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin
(all obtained from Gibco/Life Technologies, Burlington,
Ontario, Canada). Where indicated, N2a cells were trans-
fected using jetPEI reagent (Polyplus transfection/VWR;
Edmonton, Alberta, Canada) according to the manufac-
turer’s protocol, and Panx1 plasmids were a generous gift
from Dr. Dale Laird, University of Western Ontario [43,63].
N2a cells were treated at time 0 with 1 mM probenecid
or an equivalent volume of sterile water for proliferation
assays, in which cells from a minimum of three wells per
condition were counted in quintuplicate at the indicated
timepoints.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was isolated and first-strand synthesis and
PCR were carried out as described [43] using the fol-
lowing cycling parameters: 94°C for 5 minutes, 35 cycles
of 94°C for 30 seconds, 57°C for 50 seconds, and 72°C
for 2 minutes, and a final step at 72°C for 7 minutes.
Primers were: 5′-CATTGACCCCATGCTACTCC-3′,5 ′-
TCAGCCACAGAAGTCACAGG-3′ defining a 248 bp
Panx1 amplicon, accession# [GenBank: NM_019482.2)]
and 5′-TGGTGCTGAGTATGTCGTGGAGT-3′,5 ′-AGT
CTTCTGAGTGGCAGTGATGG-3′ defining a 292 bp
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
amplicon, accession# [GenBank: NM_008084.2].
Western analyses
Western analysis was performed as described [9,43].
Samples were homogenized in RIPA buffer (10 mM PBS:
150 mM NaCl, 9.1 mM dibasic sodium phosphate, 1.7 mM
monobasic sodium phosphate), 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS, protease inhibitor cock-
tail at 1 μL/10
6 cells (stock: 0.104 mM 4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride, 0.08 mM apro-
tinin, 4 mM bestatin hydrochloride, 1.4 mM N-(trans-
epoxysuccinyl)-L-leucine 4-guanidinobutylamide, 2 mM
leupeptin hemisulfate salt, 1.5 mM pepstatin-A; Sigma-
Aldrich) for 30 minutes and centrifuged for 20 minutes
at 12,000 rpm to remove debris. For all Western blots,
SDS-PAGE was performed under reducing conditions
(dithiothreitol (DTT) and β-mercaptoethanol) without
heating.
ATP release assay
N2a cells were plated at a density of 1.8×10
4 cells/cm
2
24 hours prior to ATP assay. Media was removed and
cells were washed once with Hank’s balanced salt solu-
tion (HBSS; 137.93 mM NaCl, 5.33 mM KCl, 1.26 mM
CaCl2, 0.9 mM MgCl2, 5.56 mM D-glucose, 0.441 mM
KH2PO4, 4.17 mM NaHCO3, 0.338 mM Na2HPO4) and
pre-incubated for 10 minutes in HBSS with or without
the addition of 0.5 mM probenecid. Eighty percent of
the pre-incubation medium was removed, and replaced
with an equal volume of high KCl HBSS (117.93 mM
N a C l ,2 5m MK C l ,1 . 2 6m MC a C l 2, 0.9 mM MgCl2,
5.56 mM D-glucose, 0.441 mM KH2PO4,4 . 1 7m M
NaHCO3,0 . 3 3 8m MN a 2HPO4) for a final concentration
of 20 mM KCl with or without 0.5 mM probenecid, for
10 minutes. Eighty percent of the treatment medium
was removed, spun down for 1 minute at 13,500 rpm,
and the top portion was analyzed in triplicate for ATP
concentration using an ATP determination kit from
Molecular Probes/Life Technologies, Burlington, Ontario,
Canada). Data are from five independent replicates and
were normalized to cell number.
Confocal microscopy
Neurosphere, P15, P30 and P60 mouse brain cryopreser-
vation, serial cryosectioning (10 μm for neurosphere,
20 μm for brain) were performed as described [10,44,64].
Antibodies were diluted in 10 mM PBS supplemented
with 0.3% Triton-X-100 and 3% BSA. Primary antibodies
were: rabbit polyclonal anti-Panx1 Cterm (1:40 Invitrogen),
rat monoclonal anti-GFAP (1:40, Invitrogen/Life Technolo-
gies, Burlington, Ontario, Canada), mouse monoclonal anti-
nestin (1:100, Chemicon/Millipore, Temecula, California,
USA), guinea pig polyclonal anti-doublecortin (DCX; 1:800,
Wicki-Stordeur et al. Neural Development 2012, 7:11 Page 8 of 10
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β-tubulin (1:250, RDI). Secondary antibodies were Cy3-
conjugated anti-rabbit IgG (1:600), DyLight488-conjugated
anti-rabbit IgG (1:100), Cy3-conjugated anti-guinea-pig IgG
(1:800), DyLight488-conjugated anti-mouse IgG (1:600), and
DyLight649-conjugated anti-mouse IgG (1:400). Hoechst
33342 (1 μg/mL) was used as a nuclear counterstain. To
label N2a cell membranes, cells were treated with 5 μg/mL
TRITC-conjugated wheat germ agglutinin (WGA, Molecu-
lar Probes/Life Technologies) for 5 minutes at 37°C in HBSS
(137 mM NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.44 mM
KH2PO4, 4.2 mM NaHCO3; Gibco/Life Technologies),
washed in HBSS, fixed in 3.7% paraformaldehyde for
15 minutes and processed for immunostaining. Confocal
immunofluorescence imaging was performed on a Zeiss
LSM 700 confocal microscope and images were cap-
tured sequentially with ZEN 2009 software on an EC
Plan-Neofluar 40x/1.30 oil DIC M27 objective with equal
optical slices for multiple fluorophores (approximately 1
Airy Unit) through z-stacks in 0.35 μm optical sections.
Statistical analyses
Significance was determined using Student’st tests or
ANOVA with Tukey multiple comparisons post-hoc test.
Variances are reported as standard error of the mean.
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